KYNB:NASDAQ
Kyntra Bio Inc
$7.98
arrow_downward
-0.81%(-0.065) 1D
Sep 10, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$8.42
High
$8.42
Low
$7.03
Mkt. cap
32.29M
Avg. vol.
15.04K
Volume
3.00
P/E ratio
0.18
52-wk high
$9.70
52-wk low
$6.32
EPS
$45.30
Beta
1.06
Shares outstanding
4.05M
No. of employees
34
Open
$8.42
High
$8.42
Low
$7.03
Mkt. cap
32.29M
Avg. vol.
15.04K
Volume
3.00
P/E ratio
0.18
52-wk high
$9.70
52-wk low
$6.32
EPS
$45.30
Beta
1.06
Shares outstanding
4.05M
No. of employees
34
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 week ago
Kyntra Bio (KYNB) Edges Higher to $8.02, Up 0.25% as Stock Holds Between Key Levels - EMA Signal
https://www.dars.gov.et/
·
2 months ago
Kyntra Bio Inc. (KYNB) Edges Higher on Above-Average Volume, Tests Key Resistance Zone - Bullish Pattern Stocks
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitekyntrabio.com